SmartCancer Master Guide: Cancer Types, Biomarkers, Treatment, Resistance & Precision Oncology
Precision Oncology, Cancer Biology, Biomarkers, Treatment, Resistance & Evidence
SmartCancer.org is designed to help patients, caregivers, researchers and health professionals understand cancer as a connected biological and clinical system rather than as a collection of isolated articles.
Cancer is not one disease. Even people with the same cancer diagnosis can have different tumor biology, biomarkers, disease stages, treatment histories, immune environments and mechanisms of resistance.
That is why the SmartCancer model connects:
↓
HISTOLOGY + STAGE
↓
BIOMARKERS + GENOMICS
↓
TUMOR BIOLOGY
↓
TREATMENT OPTIONS
↓
RESPONSE MONITORING
↓
RESISTANCE
↓
REPROFILING
↓
NEXT STRATEGY
↓
CLINICAL TRIALS
This Master Guide is the central navigation layer for SmartCancer.org. It connects the major cancer-information systems and provides a framework for understanding where each topic fits.
Start Here
New to Cancer Research?
Start with the Precision Oncology Guide to understand genomics, biomarkers and personalized cancer care.
Trying to Understand a Diagnosis?
Use the Cancer Genomic & Biomarker Report Guide to understand common molecular-report terminology.
Researching Treatment?
Read Cancer Treatment Options Explained for an overview of modern treatment categories.
Looking for a Clinical Trial?
Start with the SmartCancer Clinical Trials Guide.
SmartCancer's Core Principle
The traditional cancer-information model is often:
Cancer Type → Standard Treatment
Modern precision oncology increasingly adds several more layers:
Cancer Type → Histology → Stage → Biomarkers → Biology → Treatment → Response → Resistance → Reprofiling
The purpose of SmartCancer is not to replace clinical oncology. It is to make the relationships between these layers easier to understand.
01. Cancer Types & Disease States
The first layer is the cancer itself.
SmartCancer should ultimately provide dedicated knowledge hubs for major cancer types, with each hub connected to pathology, staging, biomarkers, treatments, resistance and clinical trials.
| Cancer Hub | Key SmartCancer Connections |
|---|---|
| Lung Cancer | NSCLC, SCLC, EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, HER2, NTRK, PD-L1 and resistance |
| Breast Cancer | ER, PR, HER2, BRCA, HRD, ESR1, endocrine therapy, targeted therapy and ADCs |
| Colorectal Cancer | KRAS, NRAS, BRAF, MSI-H, dMMR, HER2, EGFR, immunotherapy and ctDNA |
| Prostate Cancer | Androgen receptor biology, BRCA/HRR, PSMA, PARP-directed treatment and radioligand therapy |
| Pancreatic Cancer | KRAS, DNA repair, molecular subtypes, treatment resistance and emerging therapies |
| Ovarian Cancer | BRCA, HRD, PARP strategies, ADCs and immunotherapy |
| Melanoma | BRAF, immune biology, checkpoint therapy and resistance |
| Hematologic Cancers | Leukemias, lymphomas, myeloma, CAR-T, bispecific antibodies and targeted therapies |
Future architecture: every major cancer page should eventually answer the same questions: What is the cancer? How is it diagnosed? How is it staged? Which biomarkers matter? What treatments are used? How is response measured? Why can resistance develop? What should happen after progression? Which clinical trials may be relevant?
02. Diagnosis, Pathology & Staging
Precision oncology begins with an accurate diagnosis.
Diagnosis may involve pathology, imaging, laboratory testing, immunohistochemistry, molecular testing and other diagnostic methods depending on the cancer.
Stage and histology remain foundational. Biomarkers add another layer; they do not replace the underlying diagnosis or staging system.
SmartCancer's long-term cancer pages should therefore connect:
- Primary cancer site
- Histologic subtype
- Grade and pathology
- TNM or disease-specific staging
- Metastatic sites and disease status
- Molecular and immune biomarkers
03. Biomarkers & Cancer Genomics
Biomarkers are one of the central building blocks of the SmartCancer knowledge graph.
The Cancer Biomarkers Guide covers major genomic, molecular and immune biomarkers and explains how they can influence diagnosis, prognosis, treatment selection, monitoring and resistance analysis.
Major biomarker families include:
| Family | Examples | Typical Question |
|---|---|---|
| Oncogenic Drivers | EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, NTRK | Is there a targetable driver? |
| Tumor Suppressors / DNA Repair | BRCA1, BRCA2, PALB2, TP53, HRD | Is DNA-repair biology clinically relevant? |
| Immune Biomarkers | PD-L1, MSI-H, dMMR, TMB, TILs | Could immune-directed therapy be relevant? |
| Monitoring Biomarkers | ctDNA, MRD, selected tumor markers | Is disease changing over time? |
Key Biomarker Guides
EGFR Inhibitors | PD-L1 | TMB
Future dedicated SmartCancer biomarker hubs should include KRAS, HER2, ALK, BRAF, RET, MET, NTRK, MSI-H/dMMR, BRCA/HRD, ESR1, PIK3CA, IDH1/2, FLT3 and other clinically meaningful biomarkers.
04. How to Read a Cancer Genomic Report
The Cancer Genomic & Biomarker Report Guide provides a patient-friendly bridge between a laboratory report and the clinical questions that matter.
The key principle is:
A report should not be interpreted as an isolated list of mutations. Its meaning depends on cancer type, pathology, stage, treatment history, assay characteristics and available clinical evidence.
05. Cancer Treatment
SmartCancer's Cancer Treatment Options Guide provides the broad treatment map.
Major treatment categories include:
- Surgery
- Radiation therapy
- Chemotherapy
- Hormone or endocrine therapy
- Targeted therapy
- Immunotherapy
- Antibody-drug conjugates
- Bispecific antibodies
- CAR-T and other cellular therapies
- Radioligand and radiopharmaceutical therapies
- Clinical trials and investigational therapies
- Supportive, palliative and survivorship care
The goal is not to create a single universal treatment list. The goal is to explain where each treatment fits in the cancer-specific decision system.
06. Immunotherapy
Immunotherapy is a major pillar of modern oncology, but it is not a single treatment category.
SmartCancer's future immunotherapy architecture should connect:
- PD-1 and PD-L1 inhibitors
- CTLA-4 inhibitors
- LAG-3 and emerging immune checkpoints
- Bispecific antibodies
- TIL therapy
- CAR-T and engineered cellular therapies
- Cancer vaccines
- Immune biomarkers
- Tumor microenvironment
- Primary and acquired immunotherapy resistance
The essential SmartCancer rule is that immune therapy should always be interpreted in the context of cancer type, biomarker profile, disease state and treatment history.
07. Targeted & Molecular Therapy
Precision oncology increasingly asks which biological alteration is driving or supporting a tumor rather than relying exclusively on its anatomical location.
SmartCancer already has a dedicated EGFR treatment and resistance guide.
Future molecular hubs should systematically connect each major biomarker to:
- Biological pathway
- Relevant cancer types
- Approved treatment classes
- Clinical-trial approaches
- Resistance mechanisms
- Monitoring strategies
- Known limitations and evidence level
08. Cancer Treatment Resistance
Resistance is not an optional topic. It should be one of the defining SmartCancer pillars.
The SmartCancer resistance model is:
↓
TREATMENT PRESSURE
↓
SELECTION / ADAPTATION
↓
RESISTANT POPULATION
↓
PROGRESSION
↓
REPROFILING
↓
NEXT STRATEGY
Resistance may involve on-target alterations, bypass pathways, tumor heterogeneity, immune escape, microenvironmental protection, lineage change, epigenetic adaptation or other biological processes.
The New Blueprint for Cancer Treatment expands this concept into longitudinal monitoring, heterogeneity, plasticity and adaptive treatment design.
09. Monitoring, Liquid Biopsy, ctDNA & MRD
Cancer is dynamic. Treatment therefore cannot always be understood from a single biopsy or a single scan.
SmartCancer's monitoring layer should connect:
- CT
- MRI
- PET
- Pathology
- Tumor markers
- Liquid biopsy
- Circulating tumor DNA
- Minimal residual disease
- Repeat tissue biopsy when clinically appropriate
The objective is to understand not simply whether cancer is present, but whether its biology is changing.
10. Clinical Trials
The SmartCancer Clinical Trials Guide treats trial matching as a precision-oncology problem.
The core model is:
Cancer Type + Stage + Biomarkers + Previous Treatment + Disease Status → Trial Eligibility
SmartCancer should increasingly organize trial information around:
- Biomarker-selected trials
- Basket trials
- Umbrella trials
- Platform trials
- Resistance-directed studies
- Cellular therapies
- New targeted therapies
- Novel immunotherapies
- Personalized cancer vaccines
11. Evidence: SmartCancer E0–E5 Framework
SmartCancer needs one consistent evidence system across the entire website.
The current Knowledge Graph uses E0–E5. This should become the site's primary house framework.
| Level | Meaning | Typical Evidence |
|---|---|---|
| E0 | Hypothesis | Theoretical or mechanistic concept |
| E1 | Preclinical | Cell, animal or laboratory studies |
| E2 | Early Clinical | Early human studies or preliminary clinical evidence |
| E3 | Comparative Evidence | Meaningful controlled or comparative evidence |
| E4 | Established Evidence | Substantial evidence for defined clinical use |
| E5 | Standard / Guideline-Supported | Established use supported by authoritative guidance |
E0–E5 is a SmartCancer editorial framework, not a replacement for formal clinical guideline systems or a claim that all evidence can be reduced to one numerical scale.
12. Conventional, Emerging & Experimental Oncology
SmartCancer should deliberately keep different evidence categories separate.
| Category | How SmartCancer Should Present It |
|---|---|
| Guideline-supported | Clearly identified as established clinical care where applicable |
| Established clinical evidence | Describe the population, endpoints and limitations |
| Emerging clinical research | Highlight uncertainty and research status |
| Preclinical | Mechanistic or laboratory evidence only |
| Anecdotal / testimonial | Hypothesis-generating, never equivalent to clinical efficacy evidence |
13. Integrative & Repurposed Oncology
SmartCancer can continue covering metabolic oncology, repurposed drugs and experimental interventions, but these topics should sit inside the broader precision-oncology architecture rather than define the entire site.
The 30 Repurposed and Alternative Cancer Interventions review is an example of the appropriate evidence-graded model.
The same rule should apply to ivermectin, fenbendazole, mebendazole, metformin, metabolic interventions, supplements and other experimental approaches:
Mechanism ≠ Clinical Efficacy
Case Reports ≠ Clinical Trial Evidence
Promising ≠ Proven
Investigational ≠ Standard Care
14. The SmartCancer Oncology Matrix
This matrix should eventually become one of the site's most valuable information assets.
| Cancer | Biomarker / Biology | Treatment Class | Resistance / Monitoring |
|---|---|---|---|
| NSCLC | EGFR | EGFR-targeted therapy | Acquired resistance, repeat profiling, ctDNA |
| NSCLC | ALK | ALK-targeted therapy | Resistance alterations, CNS monitoring |
| Breast | HER2 | HER2-directed therapy / ADCs | Heterogeneity, target loss, pathway bypass |
| Colorectal | MSI-H / dMMR | Immune checkpoint therapy in appropriate settings | Primary/acquired immune resistance |
| Prostate | AR / HRR / PSMA | Hormonal, PARP-directed, radioligand approaches | AR adaptation, lineage change, target heterogeneity |
This is an educational navigation framework, not an automated treatment-selection tool.
15. The New SmartCancer Content Architecture
Every important SmartCancer article should ideally belong to one of these connected systems:
- Cancer Type
- Diagnosis & Pathology
- Stage & Disease State
- Biomarkers & Genomics
- Tumor Biology
- Treatment
- Immunotherapy
- Resistance & Tumor Microenvironment
- Monitoring & Liquid Biopsy
- Clinical Trials
- Supportive Care & Survivorship
- Emerging / Experimental Research
The value is not simply the number of articles. The value is the number of meaningful relationships between them.
16. What Makes SmartCancer Different?
- Patient-first: Start with the questions patients and families actually ask.
- Biology-first: Connect cancer diagnosis to molecular and immune biology.
- Resistance-aware: Treat treatment failure as a core part of the story.
- Evidence-aware: Separate established care from emerging science.
- Multi-modal: Explain how different treatment classes fit together when evidence supports combination strategies.
- Longitudinal: Track how cancer can change over time.
- AI-ready: Organize content around entities and relationships rather than isolated keyword articles.
17. How to Use SmartCancer as a Patient or Caregiver
SmartCancer should help readers move from a broad diagnosis toward better questions for their oncology team.
Step 1: Confirm the exact cancer and pathology.
Step 2: Understand the stage and disease status.
Step 3: Identify which biomarkers have been tested.
Step 4: Understand the treatment options relevant to that cancer.
Step 5: Ask how response will be measured.
Step 6: Understand what resistance or progression could mean.
Step 7: Ask whether repeat molecular testing or a clinical trial is relevant.
18. SmartCancer's Recommended Core Resources
Oncology Knowledge Graph
Precision Oncology Guide
Cancer Biomarkers Guide
Genomic & Biomarker Report Guide
Cancer Treatment Options Guide
Cancer Clinical Trials Guide
New Blueprint for Cancer Treatment
EGFR Inhibitors Guide
TMB Guide
PD-L1 Guide
CAR-T Cell Therapy Guide
19. Where SmartCancer Should Go Next
The next stage should not simply be “more articles.” It should be the construction of a true oncology information architecture.
The priority sequence is:
MASTER GUIDE
↓
SITE INDEX
↓
CANCER TYPE HUBS
↓
BIOMARKER HUBS
↓
TREATMENT HUBS
↓
RESISTANCE HUBS
↓
MONITORING HUBS
↓
CLINICAL TRIAL HUBS
↓
CANCER × BIOMARKER × TREATMENT × RESISTANCE MATRICES
Once those layers exist, SmartCancer can evolve from a Blogger publication into a structured cancer knowledge platform that is much easier for patients, search engines and AI systems to understand.
Medical Disclaimer
This website is for educational and informational purposes only and is not medical advice, diagnosis or individualized treatment guidance. Cancer treatment depends on the specific diagnosis, pathology, stage, molecular profile, previous treatment, patient factors and goals of care. Readers should discuss cancer testing and treatment decisions with appropriately qualified healthcare professionals.
SmartCancer.org — Precision Oncology, Cancer Biology & Evidence
.png)
.png)
.png)
Comments
Post a Comment